Edition:
United Kingdom

Mersana Therapeutics Inc (MRSN.OQ)

MRSN.OQ on NASDAQ Stock Exchange Global Select Market

16.85USD
23 Apr 2018
Change (% chg)

$0.18 (+1.08%)
Prev Close
$16.67
Open
$16.80
Day's High
$17.11
Day's Low
$16.70
Volume
26,700
Avg. Vol
42,240
52-wk High
$21.01
52-wk Low
$12.65

Chart for

About

Mersana Therapeutics, Inc. is a biotechnology company. The Company is focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design... (more)

Overall

Beta: --
Market Cap(Mil.): $380.84
Shares Outstanding(Mil.): 22.85
Dividend: --
Yield (%): --

Financials

  MRSN.OQ Industry Sector
P/E (TTM): -- 188.22 33.60
EPS (TTM): -1.70 -- --
ROI: -44.10 -0.74 13.19
ROE: -538.52 -2.80 15.00

BRIEF-Mersana Therapeutics Q4 Loss Per Share $0.61

* MERSANA THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATES

28 Mar 2018

BRIEF-Mersana Appoints David Spellman As Chief Financial Officer

* MERSANA APPOINTS DAVID A. SPELLMAN AS CHIEF FINANCIAL OFFICER

12 Mar 2018

BRIEF-Mersana Announces First Patient Dosed With XMT-1536 In Phase 1 Study In Patients With NaPi2b-Expressing Tumors

* MERSANA ANNOUNCES FIRST PATIENT DOSED WITH XMT-1536 IN PHASE 1 STUDY IN PATIENTS WITH NAPI2B-EXPRESSING TUMORS Source text for Eikon: Further company coverage:

12 Dec 2017

BRIEF-Mersana announces third quarter loss of $0.35 per share

* Mersana announces third quarter 2017 financial results and provides business updates

09 Nov 2017

BRIEF-Mersana announces FDA clearance of IND application for XMT-1536

* Mersana announces FDA clearance of IND application for XMT-1536, a first-in-class antibody drug conjugate targeting NaPi2b

30 Oct 2017

Earnings vs. Estimates